Research for new therapeutic targets in multiple sclerosis

2014 Fiscal Year Final Research Report

• Project/Area Number: 25670256
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Applied pharmacology
• Research Institution: Chiba University
• Principal Investigator: KASUYA Yoshitoshi 千葉大学, 医学(系)研究科(研究院), 准教授 (70221877)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: 多発性硬化症 / 実験的自己免疫性脳脊髄炎 / p38 / エンドセリン

Outline of Final Research Achievements

To research new therapeutic targets in multiple sclerosis, experimental autoimmune encephalomyelitis was conducted, and the following results were obtained. (1) Using p38α+/- mice resistant to the pathogenesis of EAE, plausible candidates involved in the development of EAE were evaluated. A DNA array analysis with the spinal cord samples showed that a significant difference in mRNA expression of sphingosine kinase 1, urokinase receptor, Ask2, Hexokinase 3 and STK32A was observed between WT and p38α+/- mice. (2) A bioactive substance, endothelin (ET) can regulate IL-17 production in Th17 cells through ETA receptor.

Free Research Field

医歯薬学